Quarter two presentation August 20, Jan Erik Hedborg, CEO

We make a recognized difference for life ContextVision - s ets the standard for image analysis and enhancement 2 VISION

Agenda  Operational highlights  Financial highlights  Market performance Q2  Europe  USA  Asia  COV´s way forward

Q2 - operational highlights  GOPView® iRV contract with global manufacturer signed  Positive clinical study of GOPiCE® US from leading U.S. hospital stating significant better performance compared to current state-of-the image enhancement  Continued high activity level on product development and clinical validation (next generation volumetric/3D product – GOPiCE MR – for MRI initiated) 4

Q1 – Financial highlights  Lower Q2 sales - negatively impacted by lower demand mainly due to the financial downturn and increased competition within ultrasound  Cost increased – mainly due to higher personnel costs and higher sales, marketing and clinical studies 5

Market performance Q2 – USA  Decline in ultrasound volumes due to competition  Revenue impacted by financial downturn  Well positioned for new GOPView iRV and GOPiCE US business 6

Market performance Q2 – Europe 7  Strong X-ray and mammography potential  Ultrasound sales weaker  Well positioned for new GOPView iRV and GOPiCE US business

Market performance Q2 – Asia 8  Decline in ultrasound volumes  China remains uncertain due to the economical turmoil  Well positioned for new GOPView iRV and GOPiCE US business in Japan & Korea

Sales by product Q2  XR growth through recent contracts and is expected to continue  Weaker ultrasound demand in all three regions (USA, Europe & Asia)  GOPView iRV will start to generate license revenues in Q4 9 Angiography system (GOPView iRV application)

Financial performance 10 Income statment  Revenue affected by lower demand generated by the financial crisis and higher competition in ultrasound  Personnel cost higher due to strategic recruitments

Financial performance 11 Balance sheet  Development work for GOPView iRV and GOPiCE US activated during 2008/2009  Financial assets consist of shares in SharpView – adjusted to market value  Cash 16MSEK

Financial performance 12 Cash flow  Assets represent GOPiCE US and GOPView iRV

13 COV´s way forward  Generate increased revenues from GOPView iRV, GOPiCE US and other existing products (XR, MAMMO)  Introduce GOPiCE MR (2010), GOPView XR3, GOPView US3 and GOPiCE CT (subject to go/no go decisions)  Expand business with tier 1 manufacturer´s  Strengthen COV branding & IPR  Develop new product concepts

Thank You! 14